Metformin ‘useless’ in low-risk prediabetes

The US study of 3000 people with impaired glucose metabolism found not all patients benefited from metformin compared to lifestyle intervention.

“They have shown that the highest-risk group is almost entirely responsible [for metformin’s beneficial results] whereas the other three quarters didn’t respond at all, pretty much. It was a fairly useless treatment in the lowest three quartiles,” Associate Professor Neale Cohen, general manager of diabetes services at Baker IDI, said.

The researchers took data from one of the landmark studies